Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mwesige Charles

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
African Journal of Laboratory Medicine|October 26, 2020
Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, TanzaniaErius Tebuka, Mwesige Charles, Jeffer O Bhuko
Journal of Blood Medicine|January 30, 2023
Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western TanzaniaEmmanuela E Ambrose, Benson R Kidenya, Mwesige Charles, et al.
Frontiers in Molecular Biosciences|June 16, 2023
Hydroxyurea pharmacokinetics and precision dosing in low-resource settingsLuke R Smart, Mwesige Charles, Kathryn E McElhinney, et al.
The Lancet. Haematology|March 4, 2023
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trialEmmanuela E Ambrose, Teresa S Latham, Primrose Songoro, et al.
Bulletin of the World Health Organization|December 9, 2020
Surveillance for sickle cell disease, United Republic of TanzaniaEmmanuela E Ambrose, Luke R Smart, Mwesige Charles, et al.
Acta Haematologica|August 17, 2022
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan AfricaLuke R Smart, Emmanuela E Ambrose, Georgina Balyorugulu, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
African Journal of Laboratory Medicine|October 26, 2020
Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, TanzaniaErius Tebuka, Mwesige Charles, Jeffer O Bhuko
Journal of Blood Medicine|January 30, 2023
Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western TanzaniaEmmanuela E Ambrose, Benson R Kidenya, Mwesige Charles, et al.
Frontiers in Molecular Biosciences|June 16, 2023
Hydroxyurea pharmacokinetics and precision dosing in low-resource settingsLuke R Smart, Mwesige Charles, Kathryn E McElhinney, et al.
The Lancet. Haematology|March 4, 2023
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trialEmmanuela E Ambrose, Teresa S Latham, Primrose Songoro, et al.
Bulletin of the World Health Organization|December 9, 2020
Surveillance for sickle cell disease, United Republic of TanzaniaEmmanuela E Ambrose, Luke R Smart, Mwesige Charles, et al.
Acta Haematologica|August 17, 2022
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan AfricaLuke R Smart, Emmanuela E Ambrose, Georgina Balyorugulu, et al.
Pageof 1